Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer

We report three signatures produced from SHARPIN gene copy number increase (GCN-Increase) and their effects on patients with breast cancer (BC). In the Metabric dataset (n=2059, cBioPortal), SHARPIN GCN-Increase occurs preferentially or mutual exclusively with mutations in TP53, PIK3CA, and CDH1. These genomic alterations constitute a signature (SigMut) that significantly correlates with reductions in overall survival (OS) in BC patients (n=1980; p=1.081e-6). Additionally, SHARPIN GCN-Increase is associated with 4,220 differentially expressed genes (DEGs). These DEGs are enriched in activation of the pathways regulating cell cycle progression, RNA transport, ribosome biosynthesis, DNA replication, and in downregulation of the pathways related to extracellular matrix. These DEGs are thus likely to facilitate the proliferation and metastasis of BC cells. Additionally, through forward (FWD) and backward (BWD) stepwise variate selections among the top 160 downregulated and top 200 upregulated DEGs using the Cox regression model, a 6-gene (SigFWD) and a 50-gene (SigBWD) signature were derived. Both signatures robustly associate with decreases in OS in BC patients within the Curtis (n=1980; p=6.16e-11 for SigFWD; p=1.06e-10, for SigBWD) and TCGA cohort (n=817; p=4.53e-4 for SigFWD and p=0.00525 for SigBWD). After adjusting for known clinical factors, SigMut (HR 1.21, P=0.0297), SigBWD (HR 1.25, P=0.0263), and likely SigFWD (HR 1.17, p=0.062) remain independent risk factors of BC de...
Source: BBA Clinical - Category: Biochemistry Source Type: research